Skip to content
OpenCapital
Get started

LivaNova LIVN Neuromodulation — Net revenue

Other segment segments

Cardiopulmonary
$208.66M+18.3%

Similar metrics at other companies

Boston Scientific logo
BSXNeuromodulation — Net Sales
$318M+17.3%
Medtronic logo
MDTNeuroscience — Net Sales
$2.75B+5.0%
AbbVie logo
ABBVOther Neuroscience — Net revenues
$125M-19.4%
Amneal Pharmaceuticals, Inc. logo
AMRXCentral nervous system — Net revenue
$83.38M+23.3%
Stryker logo
SYKMedSurg and Neurotechnology: — Net Sales
$3.21B+4.9%
Eli Lilly logo
LLYNeuroscience — Revenue
$382M+40.4%

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.31B+62.8%
Enterprise value$4.11B+58.0%
P/S3×+0.9×

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's neuromodulation — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's neuromodulation — net revenue?
LivaNova (LIVN) reported neuromodulation — net revenue of $151.79M in Q1 2026.
How has LivaNova's neuromodulation — net revenue changed year-over-year?
LivaNova's neuromodulation — net revenue increased by 9.3% year-over-year, from $138.89M to $151.79M.
What is the long-term trend for LivaNova's neuromodulation — net revenue?
Over 4 years (2021 to 2025), LivaNova's neuromodulation — net revenue has grown at a 6.8% compound annual growth rate (CAGR), from $456.17M to $592.81M.
What does neuromodulation — net revenue mean?
Represents the total gross sales generated by the Neuromodulation business segment after deducting returns, allowances, and discounts. This metric serves as a primary indicator of market demand and the segment's ability to scale its medical device product offerings.